REFERENCES

• EhmannTS.BeningerRJ.GawelMJ.RiopelleRJ.Depressive symptoms in Parkinson's disease: a comparison with disabled and control subjects.J Geriatr Psychiatr Neurol.1990339
   PubMedGoogle Scholar
• ScottB.BorgmanA.EnglerH.et al.Gender differences in Parkinson's disease symptom profile.Acta Neurol Scand.2000102374310893061
   PubMed Web of Science ®Google Scholar
• SchragA.JahanshahiM.QuinnNP.What contributes to depression in Parkinson's disease?Psychol Med.200131657311200961
   PubMed Web of Science ®Google Scholar
• HantzP.Caradoc-DaviesG.Caradoc-DaviesT.et al.Depression in Parkinson's disease.Am J Psychiatry.1994151101010148010356
   PubMedGoogle Scholar
• RojoA.AguilarM.GaroleraMT.et al.Depression in Parkinson's disease: clinical correlates and outcome.Parkinsonism Relat Disord.200310232814499203
   PubMed Web of Science ®Google Scholar
• MayeuxR.SternY.CoteL.WilliamsJBW.Altered serotonin metabolism in depressed patients with Parkinson's disease.Neurology.1984346426466200801
   PubMed Web of Science ®Google Scholar
• MayeuxR.SternY.SanoM.et al.The relationship of serotonin to depression in Parkinson's disease.Mov Disord.198832372442461509
   PubMed Web of Science ®Google Scholar
• WolfeN.KatzDl.AlbertML.et al.Neuropsychological profile linked to low dopamine in Alzheimer's disease, major depression, and Parkinson's disease.J Neurol Neurosurg Psychiatry.1990539159172266376
   PubMed Web of Science ®Google Scholar
• KuhnW.MullerT.GerlachM.et al.Depression in Parkinson's disease: biogenic amines in CSF of “de novo” patients.J Neural Transm.1996103144114459029411
   PubMed Web of Science ®Google Scholar
• MaybergHS.StarksteinSE.SadzotB.et al.Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease.Ann Neurol.19902857642375634
   PubMed Web of Science ®Google Scholar
• RingHA.BenchCJ.TrimbleMR.BrooksDJ.FrackowlakRS.DolanRJ.Depression in Parkinson's disease. A positron emission study.Br J Psychiatry.19941653333397994502
   PubMed Web of Science ®Google Scholar
• StarksteinSE.PreziosiTJ.BolducPL.RobinsonRG.Depression in Parkinson's disease.J Nerv Ment Dis.199017827312295885
   PubMedGoogle Scholar
• MaricleRA.NuttJG.ValentineRJ.CarterJH.Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study.Neurology.199545175717607675241
   PubMed Web of Science ®Google Scholar
• ShulmanLM.TabackRL.RabinsteinAA.WeinerWJ.Non-recognition of depression and other non-motor symptoms in Parkinson's disease.Parkinsonism Relat Disord.2002819319712039431
   PubMed Web of Science ®Google Scholar
• WeintraubD.MobergPJ.DudaJE.et al.Recognition and treatment of depression in Parkinson's disease.J Geriatr Psychiatr Neurol.200316178183
   PubMed Web of Science ®Google Scholar
• KlassenT.VerheyFRJ.SneijdersGHJM.et al.Treatment of depression in Parkinson's disease: a meta-analysis.J Neuropsychiatry Clin Neurosci.199572812867580184
   PubMed Web of Science ®Google Scholar
• WermuthL.SorensenPS.TimmS.et al.Depression in idiopathic Parkinson's disease treated with citalopram. A placebo-controlled trial.Nord J Psychiatry.199852163169
   Web of Science ®Google Scholar
• ChungTH.DeaneKH.Ghazi-NooriS.et al.Systematic review of antidepressant therapies in Parkinson's disease.Parkinsonism Relat Disord.200310596514643994
   PubMed Web of Science ®Google Scholar
• ShulmanLM.SingerC.LiefertR.et al.Therapeutic effects of sertraline in patients with Parkinson's disease.Mov Disord.199611603
   Web of Science ®Google Scholar
• RichardIH.KurlanR.A survey of antidepressant drug use in Parkinson's disease.Neurology.199749116811709339713
   PubMed Web of Science ®Google Scholar
• Dell'AgnelloG.CeravoloR.NutiA.et al.SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.Clin Neuropharmacol.20012422122711479393
   PubMed Web of Science ®Google Scholar
• GoetzCG.TannerCM.KlawansHL.Bupropion in Parkinson's disease.Neurology.198434109210946431314
   PubMedGoogle Scholar
• SchifferRB.KurlanR.RubinA.BoerS.Evidence for atypical depression in Parkinson's disease.Am J Psychiatry.1988145102010223394854
   PubMed Web of Science ®Google Scholar
• SchifferRB.Anxiety disorders in Parkinson's disease: insights into the neurobiology of neurosis.J Psychosom Res.19994750550810661598
   PubMed Web of Science ®Google Scholar
• MenzaMA.Robertson-HoffmanDE.BonapaceAS.Parkinson's disease and anxiety: comorbidity with depression.Biol Psychiatry.1993344654708268331
   PubMed Web of Science ®Google Scholar
• RichardIH.SchifferRB.KurlanR.Anxiety and Parkinson's disease.J Neuropsychiatry Clin Neurosci.199683833929116473
   PubMed Web of Science ®Google Scholar
• CummingsJL.Depression and Parkinson's disease: a review.Am J Psychiatry.19921494434541372794
   PubMed Web of Science ®Google Scholar
• SteinMB.HauserIJ.JuncosJL.UhdeTW.Anxiety disorders in patients with Parkinson's disease.Am J Psychiatry.19901422172202301664
   PubMedGoogle Scholar
• HendersonR.KurlanR.KersunJM.et al.Preliminary examination of the co-morbidity of anxiety and depression in Parkinson's disease.J Neuropsychiatry Clin Neurosci.199242572661498578
   PubMed Web of Science ®Google Scholar
• PattS.GerhardL.A study of human locus coeruleus in normal brains and in Parkinson's disease.Neuropathol Appl Neurobiol.1993195195238121544
   PubMed Web of Science ®Google Scholar
• RichardIH.KurlanR.LichterD.et al.Parkinson's disease: a preliminary study of yohimbine challenge in patients with anxiety.Clin Neuropharmacol.19992217217510367182
   PubMed Web of Science ®Google Scholar
• HallidayGM.BlumbergsPC.CottonRG.et al.Loss of brainstem serotonin and substance P-containing neurons in Parkinson's disease.Brain Res.199051201041071691042
   PubMedGoogle Scholar
• AgidY.CerveraP.HirschE.et al.Biochemistry of Parkinson's disease 28 years later: a critical review.Mov Disord.1989(suppl 1)51265144
   Google Scholar
• LauterbachEC.DuvoisinRC.Anxiety disorders in familial parkinsonism.Am J Psychiatry.19921482741987832
   PubMed Web of Science ®Google Scholar
• LauterbachEC.FreemanA.VogelRL.Correlates of generalized anxiety and panic attacks in dystonia and Parkinson disease.Cogn Behav Neurol.20031622523314665822
   PubMedGoogle Scholar
• RapoportJL.WiseSP.Obsessive-compulsive disorder: evidence for basal ganglia dysfunction.Psychopharmacol Bull.1988243803843153497
   PubMedGoogle Scholar
• TomerR.LevinBE.WeinerWJ.Obsessive-compulsive symptoms and motor asymmetries in Parkinson's disease.Neuropsychiatry Neuropsychol Behav Neurol.199362630
   Google Scholar
• AlegretM.Junque'C.ValldeoriolaF.VendrellP.et al.Obsessive-compulsive symptoms in Parkinson's disease.J Neurol Neurosurg Psychiatry.20017039439611181867
   PubMed Web of Science ®Google Scholar
• FactorSA.FeustelPJ.FriedmanJH.et al.Longitudinal outcome of Parkinson's disease patients with psychosis.Neurology.2003601756176112796526
   PubMed Web of Science ®Google Scholar
• FactorSA.MolhoES.PodskalnyGD.BrownD.Parkinson's disease: druginduced psychiatric states.Adv Neurol.1995651151387872135
   PubMedGoogle Scholar
• HolroydS.CurrieL.WootenGF.Prospective study of hallucinations and delusions in Parkinson's disease. J A/euro/Neurosurg Psychiatry.200170734738
   PubMed Web of Science ®Google Scholar
• Sanchez-RamosJR.OrtoliR.PaulsonGW.Visual hallucinations associated with Parkinson's disease.Arch Neurol.199653126512688970453
   PubMed Web of Science ®Google Scholar
• AarslandD.LarsenJP.LimNG.et al.Range of neuropsychiatrie disturbances in patients with Parkinson's disease.J Neurol Neurosurg Psychiatry.19996749249610486397
   PubMed Web of Science ®Google Scholar
• PappertEJ.GoetzCG.RamonR.et al.Stability of hallucinations and illusions in Parkinson's disease: 18-month prospective study.Mov Disord.199813 (suppl)909827602
   PubMedGoogle Scholar
• AarslandD.LarsonJP.CummingsJL.et al.Prevalence and clinical correlates of psychiatric symptoms in Parkinson's disease: a community-based study.Arch Neurol.19995659560110328255
   PubMed Web of Science ®Google Scholar
• MoskovitzC.MosesH.KlawansHL.Levodopa-induced psychosis: a kindling phenomenon.Am J Psychiatry.1978135669675655276
   PubMed Web of Science ®Google Scholar
• FriedmanA.SienkiewiczJ.Psychotic complications of long-term levodopa treatment in Parkinson's disease.Acta Neurol Scand.1991841111131950448
   PubMed Web of Science ®Google Scholar
• KlawansHL.llahiMM.ShenkerE.Theoretical implications of the use of L-dopa in parkinsonism.Acta Neurol Scand.1970464094414323341
   PubMed Web of Science ®Google Scholar
• DiederichNJ.PieriV.GoetzCG.Coping strategies for visual hallucinations in Parkinson's disease.Mov Disord.20031883183212815665
   PubMed Web of Science ®Google Scholar
• DeweyRB.O'SuilleabhainPE.Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease.Neurology.2000551753175411113242
   PubMed Web of Science ®Google Scholar
• TargumSD.AbbotJL.Efficacy of quetiapine in Parkinson's patients with psychosis.J Clin Psychopharmacol.200020546010653209
   PubMed Web of Science ®Google Scholar
• SommorBR.Quetiapine-induced extrapyramidal side effects in patients with Parkinson's disease: case report.J Geriatr Psychiatry Neurol.2001149910011419575
   PubMed Web of Science ®Google Scholar
• Parkinson's Study Group.Low dose clozapine for the treatment of druginduced psychosis in Parkinson's disease.N Engl J Med.199934075776310072410
   PubMed Web of Science ®Google Scholar
• MecoG.AlessandriaA.BonifatiV.et al.Risperidone for hallucinations in levodopa-treated Parkinson's disease patients.Lancet.19942137013717514254
   PubMedGoogle Scholar
• FordB.LynchT.GreeneP.Risperidone in Parkinson's disease.Lancet.19943446817520964
   PubMed Web of Science ®Google Scholar
• EllisT.CudkowitzME.SextonPM.GrowdonJH.Clozapine and risperidone treatment of psychosis in Parkinson's disease.J Neuropsychiatry Clin Neurosci.20001236436910956570
   PubMed Web of Science ®Google Scholar
• GoetzCG.BlasucciLM.LeurgansS.PappertEJ.Olanzapine and clozapine. Comparative effects on motor function in hallucinating PD patients.Neurology.20005578979410993997
   PubMed Web of Science ®Google Scholar
• ConnemannBJ.Schonfeldt-LecuonaC.Ziprasidone in Parkinson's disease psychosis.Can J Psychiatry.2004497314763682
   PubMed Web of Science ®Google Scholar
• GrayNS.Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge.Hum Psychopharmacol.20041920520715079855
   PubMed Web of Science ®Google Scholar
• EbmeierKP.CalderSA.CrawfordJR.et al.Dementia in idiopathic Parkinson's disease: prevalence and relationship with symptoms and signs of parkinsonism.Psychol Med.19912169762047507
   PubMed Web of Science ®Google Scholar
• MayeuxR.DenaroJ.HemenegildoN.et al.A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender.Arch Neurol.1992494924971580811
   PubMed Web of Science ®Google Scholar
• TisonF.DartiguesJF.AuriacombeS.LetanneurL.BoilerF.AlperovitchA.Dementia in Parkinson's disease: a population-based study in ambulatory and institutionalized individuals.Neurology.1995457057087723958
   PubMed Web of Science ®Google Scholar
• MarderK.TangMX.CoteL.SternY.MayeuxR.The frequency and associated risk factors for dementia in patients with Parkinson's disease.Arch Neurol.1995526957017619026
   PubMed Web of Science ®Google Scholar
• AarslandD.TandbergE.LarsenJ.CummingsJL.Frequency of dementia in Parkinson disease.Arch Neurol.1996535385428660156
   PubMedGoogle Scholar
• HindleJV.Dementia in PD. In: Payfer JR, Hindle JV eds.Parkinson's Disease in the Older Patient.London, UK: Arnold 2001;XX3117
   Google Scholar
• GreenJ.McDonaldWM.VitekJL.et al.Cognitive impairments in advanced PD without dementia.Neurology.2002591320132412427877
   PubMed Web of Science ®Google Scholar
• LevyG.SchupfN.TangMX.et al.Combined effect of age and severity on the risk of dementia in Parkinson's disease.Ann Neurol.20025172272912112078
   PubMed Web of Science ®Google Scholar
• ColosimoC.HughesAJ.KilfordL.LeesAJ.Lewy body cortical involvement may not always predict dementia in Parkinson's disease.J Neurol Neurosurg Psychiatry.20037485285612810766
   PubMed Web of Science ®Google Scholar
• MuratE.What causes mental dysfunction in Parkinson's disease?Mov Disord.200318(suppl6)S63S71
   Google Scholar
• TiraboschiP.HansenLA.AlfordM.et al.Cholinergic dysfunction in diseases with Lewy bodies.Neurology.20005440741110668703
   PubMed Web of Science ®Google Scholar
• MonchiO.PetridesM.DoyonJ.et al.Neural bases of set-shifting deficits in Parkinson's disease.J Neurosci.20042470271014736856
   PubMed Web of Science ®Google Scholar
• ThielA.HilkerR.KesslerJ.et al.Activation of basal ganglia loops in idiopathic Parkinson's disease: a PET study.J Neural Transm.20031101289130114628193
   PubMedGoogle Scholar
• LewisSJ.DoveA.RobbinsTW.et al.Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry.J Neurosci.2003236351635612867520
   PubMed Web of Science ®Google Scholar
• AarslandD.LaakeK.LarsenJP.JanvinC.Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled study.J Neurol Neurosurg Psychiatry.20027270871212023410
   PubMed Web of Science ®Google Scholar
• FabbriniG.BarbantiP.AuriliaC.et al.Donepezil in the treatment of hallucinations and delusions in Parkinson's disease.Neurol Sci.200223414312111620
   PubMed Web of Science ®Google Scholar
• WerberEA.RabeyJM.The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia.J Neural Transm.20011081319132511768630
   PubMed Web of Science ®Google Scholar
• BullockR.CameronA.Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.Curr Med Res Opin.20021825826412240787
   PubMed Web of Science ®Google Scholar
• ReadingPJ.LuceAK.McKeithIG.Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.Mov Disord.2001161171117411748755
   PubMed Web of Science ®Google Scholar
• AarslandD.HutchinsonM.LarsenJP.Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.Int J Geriatr Psychiatry.20031893794114533126
   PubMed Web of Science ®Google Scholar
• MerelloM.NouzeillesMl.CammarotaA.LeiguardaR.Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.Clin Neuropharmacol.19992227327610516877
   PubMed Web of Science ®Google Scholar
• RabeyJM.NissipeanuP.KorczynAD.Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease.J Neural Transm Park Dis Dement Sect.199242772821388698
   PubMedGoogle Scholar
• FischerPA.JacobiP.SchneiderE.SchonbergerB.Effects of intravenous administration of memantine in parkinsonian patients.Arzneimittelforschung.19772714871489332193
   PubMed Web of Science ®Google Scholar
• KieburtzK.Designing neuroprotection trials in Parkinson's disease.Ann Neurol.200353(suppl )S100S10712666102
   PubMedGoogle Scholar
• ShoulsonI.Where do we stand on neuroprotection? Where do we go from here?Mov Disord.199813(suppl1)46489613718
   PubMed Web of Science ®Google Scholar
• MegaMS.CummingsJL.Frontal-subcortical circuits and neuropsychiatrie disorders.J Neuropsychiatry Clin Neurosci.199463583707841807
   PubMed Web of Science ®Google Scholar
• AndersonKE.MullinsJ.Behavioral changes associated with deep brain stimulation surgery for Parkinson's disease.Curr Neurol Neurosci Rep.2003330631312930700
   PubMed Web of Science ®Google Scholar
• DoshiPK.ChhayaN.BhattMH.Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson's disease.Mov Disord.2002171084108512360564
   PubMed Web of Science ®Google Scholar
• HouetoJL.MesnageV.MalletL.et al.Behavioural disorders, Parkinson's disease and subthalamic stimulation.J Neurol Neurosurg Psychiatry.20027270170712023409
   PubMed Web of Science ®Google Scholar
• ThoboisS.MertensP.GuenotM.et al.Subthalamic nucleus stimulation in Parkinson's disease: clinical evaluation of 18 patients.J Neurol.200224952953412021940
   PubMed Web of Science ®Google Scholar
• VolkmannJ.AllertN.VogesJ.et al.Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD.Neurology.20015654855111222806
   PubMed Web of Science ®Google Scholar
• BerneyA.VingerhoetsF.PerrinA.et al.Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients.Neurology.2002591427142912427897
   PubMed Web of Science ®Google Scholar
• FonckeE.van derLC.VandewalleV.et al.Chronic bilateral stimulation of the subthalamic nucleus (STN) in 15 patients with advanced ideopathic Parkinson's disease previously treated with unilateral internal globus pallidus (GPi) stimulation.Neurology.200156(suppl 3)A272
   Web of Science ®Google Scholar
• HarizMl.JohanssonF.ShamsgovaraP.Bilateral subthalamic nucleus stimulation in a Parkinsonian patient with preoperative deficits in speech and cognition: persisting improvement in mobility but increased dependency. A case study.Mov Disord.20001513613910634253
   PubMed Web of Science ®Google Scholar
• LimousinP.KrackP.PollakP.et al.Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.N Engl J Med.1998339110511119770557
   PubMed Web of Science ®Google Scholar
• Saint-CyrJA.TrepanierLL.KumarR.et al.Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease.Brain.2000123(Pt10)2091210811004126
   PubMed Web of Science ®Google Scholar